25.02.2013 Views

Cool Chain Brochure 2013.pdf - Sofrigam

Cool Chain Brochure 2013.pdf - Sofrigam

Cool Chain Brochure 2013.pdf - Sofrigam

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

pRe-CONfeReNCe WORkshOp Day<br />

mondAy 28tH JAnuAry 2013<br />

Workshop A<br />

Dr. Mary Foster,<br />

Chair, Packaging and<br />

Storage Expert<br />

Committee,<br />

US Pharmacopeia<br />

Workshop B<br />

Andrea Graf-Gruber,<br />

Manager, Cargo Business<br />

Process and Standards,<br />

International Air<br />

Transport Association<br />

(IATA)<br />

Workshop C<br />

Richard Peck,<br />

Senior Program Manager<br />

Life Sciences, EMEA<br />

Professional Services,<br />

Sensitech EMEA B.V.<br />

Paul DellaVilla,<br />

Project Manager Life<br />

Sciences, Professional<br />

Services,<br />

Sensitech EMEA B.V.<br />

Workshop D<br />

Simon White,<br />

Director Quality<br />

Operations, Global<br />

Logistics & Supply,<br />

EMEA Region, Pfizer<br />

9.00 –<br />

12.00<br />

an update of usP general Chapter good Distribution Practices—supply<br />

<strong>Chain</strong> integrity and industry Comments<br />

A new general USP Chapter Good Distribution Practices - Supply <strong>Chain</strong> Integrity has been presented in the new issue of the USP<br />

Pharmacopeia Forum (volume 38, edition 2).<br />

Attend this workshop to talk through the important chapters of regulations, with a specific focus on supply chain integrity. The objective of the new<br />

chapter is to ensure product identity, strength, quality, purity, and safety remains intact throughout the supply chain.<br />

The main issue of the new chapter focuses on counterfeited medicines. Here are the topics which are dealt with in detail:<br />

Legal definition of counterfeit medicines (laid down in an EU Directive for Europe, in FDCA, 21 USC 321 § 201 for the USA, inexistent in some countries),<br />

• Types of counterfeit medicines<br />

• Medical consequences of counterfeit medicines<br />

• Distribution (e.g. also via internet)<br />

• How to prepare your organisation for changes to chapter <br />

A paragraph entitled “Best Practices to combat Counterfeit Drugs and Medical Devices” presents a range of measures and possibilities to combat<br />

counterfeit medicines – this workshop will give you an overview of these strategies and how you can implement them.<br />

Some of these measures include;<br />

• Packaging technologies (secured packaging, authentication and serialisation technologies, etc.)<br />

• Establishment of Pedigrees / e-Pedigrees<br />

• Use of 2D bar codes (ECC 200) or RFID tags<br />

9.00 –<br />

12.00<br />

Practical approaches for implementing iata regulations for time & temperature<br />

sensitive air Freight shipments<br />

IATA has been collaborating with supply chain stakeholders to understand and define high-standard requirements for time and temperature<br />

sensitive air freight shipments.<br />

This workshop will examine practical approaches to sensitive healthcare products transport and how to comply with the Perishable Cargo<br />

Regulations (PCR) Chapter 17, including IATA labels. The workshop will assess the current challenges in perishable air freight and discuss how<br />

these challenges are addressed in the regulation to ensure communication, processes and standards are in place to maintain the integrity and<br />

quality of the time and temperature sensitive products along the PCR supply chain.<br />

The workshop will discuss:<br />

• What is the feedback of the industry on the implementation of the IATA Time and Temperature label?<br />

• Is the industry ready to implement end to end standard processes?<br />

• The IATA’s Road Map for 2013<br />

12.30 –<br />

15.30<br />

the use of time and temperature generated Data to Create Meaningful KPis,<br />

Enabling a greater understanding of the supply <strong>Chain</strong>, Helping to safeguard<br />

Product integrity<br />

Time and temperature data related to the distribution of temperature-sensitive medicinal products is an important element of a company’s quality<br />

initiatives. Throughout the supply chain, there are many unforeseen and uncontrollable factors that can cause products to be exposed to temperatures<br />

outside of their acceptable range for storage and distribution. These variations, if not managed carefully, may result in expensive and time-consuming<br />

quarantine processes, product loss, or at worst, harm to the end user.<br />

Utilising a comprehensive data storage management tool capable of generating reports linked to Key Performance Indicators (KPIs), enables<br />

managers to review the current state of the supply chain, assessing various risks, whilst delivering critical notifications to managers in quality,<br />

logistics, distribution, warehousing, etc… These reports allow for the implementation of fast and effective preventative measures thus minimizing<br />

risks in the supply chain.<br />

The workshop will focus on two objectives:<br />

1) Look at industry best practices and the pitfalls of data collection and report generation, then;<br />

2) Outline the methods used to set up appropriate data collection processes enabling the development of meaningful KPIs, demonstrating how<br />

certain KPIs can be used to support continuous process improvement.<br />

12.30 –<br />

15.30<br />

Keeping up with the EMa: Controlled room temperature requirements<br />

This session will lead you through the top 3 anticipated challenges relating to the GDP updates. Simon is actively involved in tracking feedback for<br />

the GDP developments and will address each individually before assigning a crisis case study to you in groups. The challenges;<br />

1.Distribution under controlled room temperature<br />

Controlled room temperature implies a certain degree of control over the temperature of the storage conditions and a continuous temperature<br />

monitoring system is required for the storage of medicinal products.<br />

2.Segregation of product<br />

Many Distribution Centres export globally, what is the purpose and benefit of segregating EU product from non-EU product? What is considered<br />

a definition of ‘segregation’ (physical, electronic, both...)? All finished product batches can be considered segregated since they are – as A GMP<br />

requirement - packaged, identified and managed in such as a way to avoid cross-contamination with other product, whether for use in humans or<br />

animals and irrespective of the indication for use.<br />

3.Intermediaries<br />

What is the industry’s oversight protocol for Intermediaries in the distribution process, carriers, freight forwarders etc.? What is the most effective<br />

quality oversight method for service providers, expectations, who should be responsible...?<br />

Your Task;<br />

You will be presented with a real life case study and must work through possible solutions in your group. Each group will then feedback to the whole<br />

workshop and you will walk away with brand new strategies!<br />

RegisteR NOW<br />

phONe: +44 (0) 20 7368 9300 email: enquire@iqpc.co.uk WeB: www.cooLcHAineurope.com

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!